EKF Diagnostics Holdings plc expected its results for the first half of 2015 to show unaudited revenues of £16.8 million, around the same level as last year, despite not having materially benefited from any tender wins in the current period. Unaudited adjusted EBITDA for the period will be around £0.7 million (in the first half of 2014: £2.2 million). This reduced level of earnings reflects the continuing impact of the investment in its Molecular division.